Muhammad Abbas1, Abrar Ahmed1, Ghulam Jilany Khan2, Mirza Muhammad Faran Ashraf Baig3, Muhammad Naveed4, Reyaj Mikrani4, Tengli Cao4, Shagufta Naeem5, Meiqi Shi6, Chen Dingding7. 1. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Jiangsu Province, Nanjing, PR China; Department of Oncology, Jiangsu Cancer Hospital, Jiangsu institute of cancer research, Nanjing medical university affiliated cancer hospital Nanjing 210009, Jiangsu, PR China. 2. Jiangsu key laboratory of Drug Screening, Evaluation and Pharmacodynamics Research, China Pharmaceutical University, Nanjing, PR China; Department of Pharmacology and Therapeutics, Faculty of Pharmacy (FOP), University of Central Punjab, Lahore, Pakistan; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, PR China. Electronic address: u4574904@hotmail.com. 3. State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, PR China. 4. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Jiangsu Province, Nanjing, PR China. 5. Department of Pathology, Ayub Medical College, Abbottabad, Pakistan. Electronic address: drshaguftaanaeem@yahoo.com. 6. Department of Oncology, Jiangsu Cancer Hospital, Jiangsu institute of cancer research, Nanjing medical university affiliated cancer hospital Nanjing 210009, Jiangsu, PR China. Electronic address: meiqishi1963@163.com. 7. Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Jiangsu Province, Nanjing, PR China. Electronic address: chdd@cpu.edu.cn.
Abstract
BACKGROUND: Carcinoembryonic antigen (CEA), carbohydrate antigen (CA)-125, CA19-9, and CA72-4 are often found modulated parameters in gastric cancer. OBJECTIVE: Our present study is focused to evaluate the synchronization of these biomarkers in response to palliative chemotherapy. METHOD: A retrospective study was conducted on 216 gastric cancer patients undergoing first-line cisplatin chemotherapy along with antiangiogenic regimen. Blood samples were taken and analyzed biochemically and statistically. RESULTS: Progression occurred in 78 of 216 patients and the median progression-free survival (PFS) was 5 months. For serum CEA, the median PFS was 4 versus 7 months for elevated and normal groups respectively (P = 0.01). The median PFS for normal and elevated CA19-9 and CA72-4 was 6 vs 4 months respectively (P = 0.001). In the multivariate Cox regression model, elevated pretreatment level of CEA, CA19-9, and distant metastases were independent factors associated with increased risk of progression (P = 0.021, P = 0.000, P = 0.006, respectively). CONCLUSIONS: Conclusively, elevated pretreatment level of CEA and CA19-9 is correlated with high risk of progression and worse prognosis. Moreover, an additional antiangiogenic therapy is more effective in decreasing cancer biomarker level after palliative chemotherapy that may be correlated with therapeutic triumph.
BACKGROUND:Carcinoembryonic antigen (CEA), carbohydrate antigen (CA)-125, CA19-9, and CA72-4 are often found modulated parameters in gastric cancer. OBJECTIVE: Our present study is focused to evaluate the synchronization of these biomarkers in response to palliative chemotherapy. METHOD: A retrospective study was conducted on 216 gastric cancerpatients undergoing first-line cisplatin chemotherapy along with antiangiogenic regimen. Blood samples were taken and analyzed biochemically and statistically. RESULTS: Progression occurred in 78 of 216 patients and the median progression-free survival (PFS) was 5 months. For serum CEA, the median PFS was 4 versus 7 months for elevated and normal groups respectively (P = 0.01). The median PFS for normal and elevated CA19-9 and CA72-4 was 6 vs 4 months respectively (P = 0.001). In the multivariate Cox regression model, elevated pretreatment level of CEA, CA19-9, and distant metastases were independent factors associated with increased risk of progression (P = 0.021, P = 0.000, P = 0.006, respectively). CONCLUSIONS: Conclusively, elevated pretreatment level of CEA and CA19-9 is correlated with high risk of progression and worse prognosis. Moreover, an additional antiangiogenic therapy is more effective in decreasing cancer biomarker level after palliative chemotherapy that may be correlated with therapeutic triumph.
Authors: Mirza Muhammad Faran Ashraf Baig; Wing-Fu Lai; Anam Ahsan; Mehreen Jabeen; Muhammad Asim Farooq; Reyaj Mikrani; Muhammad Abbas; Muhammad Naveed; Said Abasse Kassim; Faisal Raza; Afzal Ahmed Dar; Muhammad Tayyab Ansari Journal: Pharm Res Date: 2020-03-30 Impact factor: 4.200
Authors: Mirza Muhammad Faran Ashraf Baig; Muhammad Abbas; Muhammad Naveed; Said Abasse Kassim; Ghulam Jilany Khan; Muhammad Sohail; Sana Ullah; Muhammad Hasnat; Komal Shah; Muhammad Tayyab Ansari Journal: J Food Drug Anal Date: 2019-04-23 Impact factor: 6.157